An investigation for investors in NASDAQ:SRNE shares was announced whether a potential acquisition of Sorrento Therapeutics Inc would be unfair.
Investors who purchased shares of the Sorrento Therapeutics Inc (NASDAQ:SRNE) and currently hold any of those NASDAQ:SRNE shares have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 – 1554.
The investigation by a law firm is at an early stage and concerns whether a potential takeover would be unfair to NASDAQ:SRNE investors.
On May 9, 2016, Sorrento Therapeutics Inc announced that early this year it engaged financial advisors to assist the company in exploring and evaluating strategic alternatives to maximize shareholder value.
Then on May 16, 2016, Sorrento Therapeutics, Inc. announced that its partner, Mabtech Ltd., has successfully completed a combined Phase 2 & 3 clinical study in China for STI-004, a biosimilar antibody for Omalizumab (Xolair®). Sorrento Therapeutics said that STI-004 met its primary endpoint in a multicenter, randomized, double-blind, placebo-controlled clinical trial.
However, given that at least one analyst has set the high target price for NASDAQ:SRNE shares at $30.00 per share, the investigation a law firm concerns whether the Sorrento Therapeutics board of Directors will undertake an adequate sales process, will adequately shop the company before entering into any transaction, will maximize shareholder value by negotiating the best price, and will act in the shareholders’ best interests in connection with a proposed sale.
Those who are current investors in NASDAQ:SRNE shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego